Immunotherapy Withdrawals Put Spotlight on Accelerated Approval
Elie Dolgin • June 1, 2021
The FDA's Accelerated Approval program is under scrutiny after four drug companies announced plans in recent months to withdraw indications for checkpoint inhibitors that, despite showing early promise, failed to demonstrate a survival benefit in confirmatory trials. The agency's Oncologic Drugs Advisory Committee will meet in late April to discuss whether six more indications for some of these same immunotherapies should be nullified as well.
Continue reading at Cancer Discovery.
Paul Mischel is championing the importance of odd rings of DNA in tumors — and their promise as targets for cancer therapy.
Edits create cells that don’t trigger an immune response, allowing implant recipient to forego immune-suppressing drugs.